Related Experiment Video
Updated: Jul 13, 2026
06:08
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
Published on: March 21, 2025
68Ga-PSMA PET/CT in biochemically recurrent prostate cancer: association with genomic data
Doris Leithner1,2, Laure Michaud3,4, Junting Zheng5
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. doris.leithner@gmail.com.
Summary
Gallium-68 PSMA PET/CT effectively detects recurrent prostate cancer, even at low PSA levels. TP53 gene alterations correlate with shorter recurrence times, suggesting integrated diagnostics for aggressive disease.
Area of Science:
- Nuclear medicine
- Oncology
- Genomics
Background:
- Prostate cancer recurrence detection remains a clinical challenge.
- 68Ga-PSMA PET/CT offers a promising imaging modality for identifying recurrent prostate cancer.
- Genomic profiling may provide insights into disease behavior.
Purpose of the Study:
- To evaluate the diagnostic performance of 68Ga-PSMA PET/CT in biochemically recurrent prostate cancer.
- To explore the association between PET imaging findings and tumor genomic alterations.
Main Methods:
- Retrospective analysis of 603 patients with biochemical recurrence or elevated PSA undergoing 68Ga-PSMA PET/CT.
- Independent review of scans by nuclear medicine physicians.
- Genetic profiling (MSK-IMPACT) performed on a subset of 239 patients.
Main Results:
- 68Ga-PSMA PET/CT detected recurrence in 59.2% of patients, with high positive predictive value (0.98).
- Detection rates increased with PSA levels, showing utility even for PSA < 0.5 ng/mL.
- TP53 mutations were associated with a shorter time to PET-confirmed biochemical recurrence (PCBR) and borderline higher SUVmax.
Conclusions:
- 68Ga-PSMA PET/CT is valuable for detecting prostate cancer recurrence, including in cases with low PSA.
- Integrated analysis of PET findings and TP53 alterations may help identify more aggressive prostate cancer phenotypes.
